← Back to Episodes
PODCAST

Your Doctor Wasn't Taught This. Your Heart Paid the Price.

August 6, 2026·11:21·Episode 96

Quick Summary

A nationwide cohort study finds that premature menopause combined with hypertension creates cardiovascular risk far beyond either factor alone — a compounding effect that's largely missing from standard risk conversations. This episode also covers new evolutionary thinking on why menopause exists at all, and a narrative review showing how little menopause training medical students actually receive.

Your Doctor Wasn't Taught This. Your Heart Paid the Price.

0:000:00

Key Takeaways

  • ✦Women with both premature menopause and hypertension face markedly elevated cardiovascular risk — significantly greater than either condition creates on its own — yet this combination is rarely flagged in routine care.
  • ✦Menopausal age is not currently integrated into standard cardiovascular risk stratification, and the new NAMS cohort study argues it should be.
  • ✦The evolutionary biology question of why menopause exists at all remains genuinely open — the grandmother hypothesis is the most developed answer, but it's not settled science.
  • ✦A 2026 narrative review in the NAMS journal found that menopause education in undergraduate medical curricula is inconsistent, under-resourced, and leaves future physicians underprepared to counsel patients.
  • ✦The gap in medical training isn't just an inconvenience — for women with premature menopause and cardiovascular risk factors, it has real clinical consequences.

Episode Script

Thanks Toni. We've got a good one today.

There's a paper out in the NAMS journal — Menopause — that I want to start with, because it's one of those findings that sounds obvious in retrospect but almost certainly isn't making it into your doctor's office yet. It's a nationwide cohort study, which means large population, real-world data, not a controlled trial with a carefully selected group of 200 women. That matters for how seriously to take it.

The finding: premature menopause and hypertension together create cardiovascular risk that is substantially higher than either condition creates on its own. Not additive — markedly elevated. The study's conclusion language is unusually direct for a research paper. It says these two factors "confer a markedly elevated risk of CVD beyond either factor alone," and it calls for menopausal age and hypertension to be integrated into cardiovascular risk stratification for postmenopausal women.

So let's sit with that for a second. Premature menopause — menopause before age 40 — is already a known cardiovascular risk factor. Earlier estrogen loss, longer time without it, longer exposure window for the downstream effects on vasculature and lipid metabolism. That part isn't new. Hypertension is obviously a cardiovascular risk factor. Everyone knows that. But the conventional approach treats these as two separate line items on a risk checklist. You have hypertension, here's your blood pressure medication. You had premature menopause, noted. What this study is saying is that treating them as separate is wrong. The combination creates a compounding effect that the individual risk scores don't capture.

My position on this is straightforward: this should change how primary care doctors assess women with premature menopause. Full stop. If you went into menopause before 40 and you have elevated blood pressure — even borderline, even "we're watching it" — that combination needs to be on the table as a cardiovascular risk conversation, not two separate observations. The study is a cohort analysis, so it establishes association rather than mechanism, and I'd want to see the methodology looked at carefully, including how they defined cardiovascular events and what they controlled for. But the direction of the finding is consistent with what we'd expect biologically, and the size of a nationwide cohort gives it more weight than a small observational study would.

The part that frustrates me is that this is 2026. We have had decades of underinvestment in women's cardiovascular research, decades of the medical community treating menopause as a reproductive footnote rather than a systemic event, and we are still — still — in a place where risk stratification tools don't account for menopausal age. The Framingham risk score, which is still widely used in primary care, doesn't ask when you went through menopause. It doesn't ask whether it was premature. That's a significant gap, and studies like this one are building the evidence base to finally close it.

If you're a listener who went through premature menopause and you have any history of elevated blood pressure, this is worth bringing up with your doctor explicitly. Not as a general "I heard something on a podcast," but as: "I've seen research suggesting that premature menopause and hypertension together create compounding cardiovascular risk — has that been factored into my care?"


Something completely different now, and I mean that in the most literal sense. There's a piece out in PubMed this week — published August 11th — asking a question that sounds almost too basic: why did menopause evolve?

It's worth pausing on that, because it's genuinely one of the more interesting open questions in evolutionary biology, and it almost never comes up in menopause conversations, which tend to understandably focus on management rather than mechanism. But the "why" question is fascinating, and the answer is less settled than most people assume.

The dominant framework for a long time has been what's called the grandmother hypothesis. The short version: menopause persisted in humans because post-reproductive women who stopped having their own children could invest that energy in supporting grandchildren — foraging, caregiving, sharing knowledge — which increased the survival and reproductive success of their descendants enough to outweigh the cost of not reproducing directly. There's decent evidence for this in hunter-gatherer population data, and there's some interesting work with killer whales, which are one of only a handful of non-human species that also undergo menopause.

But that's not the whole story. There are competing hypotheses. One involves intergenerational reproductive conflict — essentially, that as older women and younger women competed for reproductive resources from the same mates, selection pressure shifted toward younger women reproducing while older women shifted roles. Another angle focuses less on active selection for menopause and more on the aging of the reproductive system against the backdrop of extended human lifespan — the idea that menopause isn't an adaptation per se, but a consequence of the fact that we live so much longer than our reproductive systems were originally tuned for.

I find the grandmother hypothesis the most persuasive of these, partly because of the cross-species evidence, partly because of what we know about multigenerational wealth transfer and child survival in traditional societies. But I want to be honest that "most persuasive to me right now" is different from "settled." The evolutionary biology here is genuinely contested, and any piece that presents one theory as the definitive answer is oversimplifying.

What I appreciate about this question coming up at all is that it reframes menopause — not as the body failing or winding down, but as something that might have been selected for because it served a purpose. That framing has real implications for how we think about midlife women's roles, cognitive function, social knowledge, all of it. Whether or not the grandmother hypothesis is exactly right, the underlying idea that post-reproductive women are not simply a biological afterthought — that's worth sitting with.


The third thing I want to cover today is a narrative review, also in the NAMS journal, looking at menopause education in undergraduate medical curricula. This is the pipeline question: before doctors become doctors, what are they actually being taught about menopause?

The answer, according to this review, is: not much, and not consistently.

The review characterizes menopause education in medical school as under-resourced, inconsistently delivered, and leaving graduates underprepared to counsel patients. This is a narrative review, so it's synthesizing existing literature rather than generating new data, and narrative reviews have their limitations — they're not systematic, they're subject to what the authors chose to include. But the picture they're drawing is consistent with what's been reported in other contexts. There's the often-cited figure of roughly one hour of menopause-specific training in the average medical education. One hour, for a condition that affects every woman who lives long enough to reach midlife and touches sleep, cardiovascular health, bone density, cognition, mood, and sexual health simultaneously.

The review is specifically about undergraduate medical education — medical school, not residency or fellowship. And the authors make the point that this is where the foundational competencies are supposed to be built. If a student leaves medical school without a working model of menopause as a complex hormonal transition with systemic effects, no amount of continuing education later fully compensates for that gap.

This matters in a direct, practical way for the cardiovascular study I started with. If a primary care physician was never taught to think about premature menopause as a cardiovascular risk modifier — if it was a single slide in a reproductive health lecture, if it came up at all — then even when research like today's cohort study exists, the translation into clinical practice is slow. It's not that doctors are ignoring the evidence. It's that the evidence is reaching clinicians who weren't given the foundation to integrate it easily.

The review calls for more standardized, integrated menopause content across medical curricula, not just as a reproductive health topic but as a systemic medicine topic. That framing is exactly right. Menopause doesn't belong only in the ob-gyn rotation. It belongs in cardiology, in endocrinology, in psychiatry, in primary care. Anywhere a woman is going to show up with symptoms that trace back to this transition.

Whether medical schools actually move on this is a separate and somewhat less optimistic question. Curriculum change is slow, specialty politics are real, and menopause doesn't have a powerful specialty society lobbying for its piece of the training calendar the way some other areas do. But the evidence base for why it matters is getting harder to ignore. Studies like the cardiovascular cohort analysis from today help make that case in the language medical education responds to — outcomes data.

NAMS has been pushing on this for years. The review being published in their journal in 2026 suggests they're not letting it drop, and that's genuinely useful pressure to keep applying.


Sources curated automatically by the Hot Flasher pipeline.

Hot Flasher provides informational content only and does not constitute medical advice. Always consult a qualified healthcare provider for medical concerns.